BR0311375A - Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero - Google Patents

Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero

Info

Publication number
BR0311375A
BR0311375A BR0311375-2A BR0311375A BR0311375A BR 0311375 A BR0311375 A BR 0311375A BR 0311375 A BR0311375 A BR 0311375A BR 0311375 A BR0311375 A BR 0311375A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
mammal
cognitive impairment
mild cognitive
treating dementia
Prior art date
Application number
BR0311375-2A
Other languages
English (en)
Inventor
Lars Lykke
Anders Gersel Pedersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29713304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0311375(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR0311375A publication Critical patent/BR0311375A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, USO DA MESMA, E, MéTODO PARA O TRATAMENTO DE DEMêNCIA OU DANO COGNITIVO SUAVE EM UM MAMìFERO". Uma composição farmacêutica compreendendo: (a) uma quantidade efetiva de um ou mais inibidores de acetilcolinesterase ou de um seu sal farmaceuticamente aceitável e (b) uma quantidade efetiva de um ou mais antagonistas de NMDA.
BR0311375-2A 2002-05-31 2003-05-22 Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero BR0311375A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31
PCT/DK2003/000342 WO2003101458A1 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
BR0311375A true BR0311375A (pt) 2005-03-15

Family

ID=29713304

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311375-2A BR0311375A (pt) 2002-05-31 2003-05-22 Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero

Country Status (17)

Country Link
EP (1) EP1509232B1 (pt)
JP (1) JP2005528431A (pt)
AT (1) ATE414519T1 (pt)
AU (1) AU2003227516B2 (pt)
BR (1) BR0311375A (pt)
CY (1) CY1108725T1 (pt)
DE (1) DE60324788D1 (pt)
DK (1) DK1509232T3 (pt)
ES (1) ES2314200T3 (pt)
IL (1) IL165255A0 (pt)
MX (1) MXPA04011762A (pt)
NO (1) NO332754B1 (pt)
NZ (1) NZ536603A (pt)
PL (1) PL373903A1 (pt)
PT (1) PT1509232E (pt)
SI (1) SI1509232T1 (pt)
WO (1) WO2003101458A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037234A2 (en) * 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
RS51540B (en) * 2004-01-05 2011-06-30 Merz Pharma Gmbh. & Co. Kgaa. MEMANTINE FOR THE TREATMENT OF Mild to Moderate Alzheimer's Disease
CA2554617A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
JP2007529556A (ja) * 2004-03-19 2007-10-25 アクソニクス インコーポレイテッド 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
SG157415A1 (en) * 2004-11-23 2009-12-29 Adamas Pharmaceuticals Inc Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
CA2604052C (en) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
KR101213345B1 (ko) * 2005-04-28 2012-12-17 에자이 알앤드디 매니지먼트 가부시키가이샤 항치매약을 함유하는 조성물
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
MX2012006320A (es) 2009-12-02 2013-01-18 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
US20110212928A1 (en) 2010-02-09 2011-09-01 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012004103A1 (en) 2010-07-05 2012-01-12 Gambro Lundia Ab An ambulatory ultrafiltration device, related methods and a computer program product
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2013160728A1 (en) * 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014055047A1 (en) * 2012-08-31 2014-04-10 Mahmut Bilgic Combination of idebenone and donezepil
WO2014035355A1 (en) * 2012-08-31 2014-03-06 Mahmut Bilgic Pharmaceutical combination comprising idebenone and memantine
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
NZ708595A (en) * 2012-12-13 2019-06-28 H Lundbeck As Compositions comprising vortioxetine and donepezil
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2881081T3 (es) 2013-03-15 2021-11-26 Agenebio Inc Procedimientos y composiciones para mejorar la función cognitiva
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
JP6899043B2 (ja) 2015-05-22 2021-07-07 エージンバイオ， インコーポレイテッド レベチラセタムの持続放出性医薬組成物
EA038087B1 (ru) * 2016-05-18 2021-07-05 Сувен Лайф Сайенсиз Лимитед Трехкомпонентная фармацевтическая комбинация чистых антагонистов 5-ht6 рецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора, применение указанной комбинации и содержащей ее фармацевтической композиции в лечении когнитивных расстройств и способ такого лечения
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
KR101938872B1 (ko) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
TW201821068A (zh) * 2016-10-28 2018-06-16 美商查斯製藥公司 美金剛胺(memantine)組合及用途
TR201619184A2 (tr) 2016-12-22 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
MX2021014673A (es) 2019-05-31 2022-01-11 Tecnimede Soc Tecnico Medicinal Sa Combinacion de dosis fija de liberacion inmediata de memantina y donepezil.

Also Published As

Publication number Publication date
PT1509232E (pt) 2009-01-07
ATE414519T1 (de) 2008-12-15
JP2005528431A (ja) 2005-09-22
SI1509232T1 (sl) 2009-04-30
MXPA04011762A (es) 2005-03-31
AU2003227516A1 (en) 2003-12-19
CY1108725T1 (el) 2014-04-09
DK1509232T3 (da) 2009-02-23
WO2003101458A1 (en) 2003-12-11
ES2314200T3 (es) 2009-03-16
EP1509232A1 (en) 2005-03-02
NO20045434L (no) 2004-12-13
NZ536603A (en) 2007-06-29
NO332754B1 (no) 2013-01-07
EP1509232B1 (en) 2008-11-19
IL165255A0 (en) 2005-12-18
DE60324788D1 (de) 2009-01-02
PL373903A1 (en) 2005-09-19
AU2003227516B2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
TR200100054T2 (tr) Paroksetin metansülfonat
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
BR9913752B1 (pt) uso de um produto para proteÇço de tecidos, e, processo para tratamento de tecidos.
NO20005224D0 (no) BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
PT1202724E (pt) Metodo para tratamento da dor cronica utilizando inibidores mek
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
NO20012058L (no) 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
NO963506D0 (no) 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler
PT1214936E (pt) Utilizacao de derivados de tiazolidina ou pirrolidina de aminoacidos como agentes anti-hiperglicemicos
DE60010456D1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
AP2003002743A0 (en) Therapeutic combination of a cept inhibitor and atorvastatin
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
ES2178157T3 (es) Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina.
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
BR9813684A (pt) Processo para tratar o glaucoma glc1a, e, composição para controlar o glaucoma glc1a.
HUP0103078A2 (hu) Készítmények és eljárások szürkehályog kezelésére
NO981121D0 (no) Substituerte aminoforbindelser og deres anvendelse som analgetisk virksomme stoffer
AU2002214096A1 (en) Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
AU2002232400A1 (en) Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.